Table 2. Clinical and pathological status of donors and recipients.

Group	Pair No.		Major complication of recipient	Pathological findings	Immunosuppression status
Lower NTCR Group		Donor		(-)
	1	Recipient	Chronic hepatitis	Mild interface hepatitis	Tacrolimus: twice a day
			de novo HBV		Micophenolate mofetil
		Donor		(-)
	2	Recipient		Mild interface hepatitis	Tacrolimus: twice a day
					Micophenolate mofetil
					Steroid
		Donor		(-)
	3	Recipient			Tacrolimus: twice a day
			HV stenosis	Marked bridging fibrosis	Micophenolate mofetil
					Steroid
		Donor		(-)
	4	Recipient	Unstable liver function	Mild lobular hepatitis	Cyclosporine: twice a day
					Micophenolate mofetil
Comparable NTCR Group		Donor		Moderate steatosis
	5	Recipient	de novo HBV	(-)	Cyclosporine: twice a day
			(seroconversion)		Micophenolate mofetil
		Donor
	6	Recipient	Liver dysfunction	Marked bridging fibrosis	Tacrolimus: twice a day
			HV stenosis		Micophenolate mofetil
					Steroid
	7	Donor		(-)
		Recipient	None	Mild interface hepatitis	Tacrolimus: twice a day
		Donor		Moderate steatosis
	8			(NASH suspected)
		Recipient	Biliary stricture	Canalicular cholestasis	Cyclosporine: twice a day
		Donor		(-)
	9	Recipient	HV stenosis	Mild interface hepatitis	Cyclosporine: twice a day
					Micophenolate mofetil
	10	Donor		(-)
		Recipient	None	(-)	Complete cessation
	11	Donor		(-)
		Recipient	None	(-)	Tacrolimus: once a week
		Donor		Moderate steatosis
	12	Recipient	Unstable liver function	(-)	Tacrolimus: twice a day
					Micophenolate mofetil

HBV: hepatitis B virus, HV: hepatic vein, NTCR: normalized telomere centromere ratio, NASH: none-alcoholic steatotic hepatitis, (-): almost normal.

Lower NTCR group: Median NTCRs of the recipient hepatocyte was significantly lower than those of the donor.

Compatible NTCR group: Median NTCRs of the recipient hepatocyte was not significantly lower nor higher than those of the donor.